Quest Diagnostics Incorporated stock performance trend indicates that the stock price has rallied 7.2% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 17.05% . Looking at the past 52 week period, the stock price is up at 41.29% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Quest Diagnostics Incorporated has a positive value of 22.28 compared to overall market.Quest Diagnostics Incorporated is having a Relative Strength Index of 65.48 which indicates the stock is not yet over sold or over bought based on the technical indicators.
Quest Diagnostics Incorporated (NYSE:DGX) has climbed 0.28% in the past week and advanced 3.58% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 0.05% and the outperformance has advanced to 2.4% for the last 4 weeks period.
Company shares have received an average consensus rating of Hold for the current week Quest Diagnostics Incorporated (NYSE:DGX) : On Friday heightened volatility was witnessed in Quest Diagnostics Incorporated (NYSE:DGX) which led to swings in the share price. The stock opened for trading at $98.83 and hit $99.34 on the upside , eventually ending the session at $99.06, with a gain of 0.34% or 0.34 points. The heightened volatility saw the trading volume jump to 1,547,776 shares. The 52-week high of the share price is $100 and the company has a market cap of $13,620 million. The 52-week low of the share price is at $68.2 .
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Quest Diagnostics Inc was Upgraded by BofA/Merrill to Neutral on Mar 16, 2017. Company shares were Reiterated by Barclays on Mar 7, 2017 to Equal Weight, Raises Price Target to $ 98 from a previous price target of $92 .Quest Diagnostics Inc was Initiated by Deutsche Bank on Jan 18, 2017 to Buy, Price Target of the shares are set at $108.Quest Diagnostics Inc was Upgraded by Mizuho on Jan 3, 2017 to Buy, Price Target of the shares are set at $103.
Company has reported several Insider transactions to the SEC, on Mar 6, 2017, Michael E Prevoznik (SVP & General Counsel) sold 4,478 shares at 98.29 per share price.On Mar 6, 2017, Catherine T. Doherty (SVP, Group Exec. Clin. Fran.) sold 7,162 shares at 98.27 per share price.On Feb 24, 2017, John B Ziegler (director) sold 2,000 shares at 95.51 per share price.
Quest Diagnostics Inc Last issued its quarterly earnings results on Jan 26, 2017. The company reported $1.31 EPS for the quarter, beating the analyst consensus estimate by $ 0.04. Analyst had a consensus of $1.27. The company had revenue of $1861.00 million for the quarter, compared to analysts expectations of $1859.20 million. The companys revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.29 EPS.
Quest Diagnostics Inc., is the leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its national network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative new diagnostic tests and advanced healthcare information technology solutions that help improve patient care.